Skip to content

Investigation of correlation between pharmacokinetics of midazolam and DNA methylation in hepatic derived cells to predict CYP3A4 activity

Investigation of correlation between pharmacokinetics of midazolam and DNA methylation in hepatic derived cells to predict CYP3A4 activity - Investigation of correlation between pharmacokinetics of midazolam and DNA methylation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000017842
Enrollment
20
Registered
2015-06-12
Start date
2015-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy male and female

Interventions

midazolam (oral), wash out, midazolam (iv)

Sponsors

Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The investigators must ensure that all subjects being considered meet the following inclusion criteria: 1) Japanese healthy male or female who is capable to understand and sign the informed consent 2) 20-45 years of age 3) BMI 17.6-26.4 4) good health as determined by physical examination, vital signs and laboratory tests.

Exclusion criteria

Exclusion criteria: The investigators must ensure that all subjects being considered meet the following exclusion criteria or conditions: 1) history of allergy to any drugs 2) medical attention within 2 months prior to participation 3) donation of 200 mL or more of blood within 4 weeks prior to participation, or donation of component blood within 2 weeks prior to participation 4) donation of 400 mL or more of blood within 12 weeks prior to participation 5) recent (past 4 months) participation in other clinical trial for investigational new chemical entity 6) history of drug abuse 7) alcohol abuse 8) taking drugs or healthy foods which may affect drug metabolism.

Design outcomes

Primary

MeasureTime frame
pharmacokinetics of midazolam, DNA methylation levels in hepatic derived cells, and disposition of endogenous compounds

Countries

Japan

Contacts

Public ContactMiyuki Kimura

LTA Fukuoka Mirai Hospital

miyuki-kimura@lta-med.com092-662-3608

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026